CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

ASX:
CHM

2025

DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words **"believes,"** "**plans**," "**expects**," "**anticipates**," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, "Chimeric" or the "Company") to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.

CHIMERIC THERAPEUTICS

CHM: THE NEXT 10x?

Clinical Trial Update

August 2025

2025

CHIMERIC THERAPEUTICS

INVESTMENT HIGHLIGHTS

- **4 Phase 1 clinical trials**
  under 3 FDA INDs at 4 leading US centres
- **Multiple clinical updates**
  in the next 12mths
- **Experienced leadership team**
  in cell therapy clinical development
- CHM-CDH17
  the FIRST CDH17 CAR-T in clinical trials
- **First in class**
  CLTX-CAR for brain cancer
- **Robust and long life**
  patent portfolio

CORPORATE PROFILE

Exchange	ASX: CHM
Share Price	$0.003
52 Week Range	$0.003 - 0.020
Market Cap	Approx 10m
Shares on issue	~3.2B
IPO 2021	

CHM: BROAD PORTFOLIO

3 Novel cell therapies; 4 Clinical Trials

CHM CDH17

CAR-T

Technology from:

Penn
University of Pennsylvania

PHASE 1/2 TRIAL OPEN

4 sites active

CHM CORE-NK

'OFF THE SHELF' NK

Technology from:

CASE WESTERN RESERVE UNIVERSITY

PHASE 1B TRIAL OPEN	PHASE 1B TRIAL OPEN
MD Anderson	Case Western

CHM CLTX

Technology from:

City of Hope

Phase 1A completed: COH

PHASE 1B TRIAL

1 site active

FY25 IN SUMMARY

CHIMERIC THERAPEUTICS

20
25

Corporate

$16.6m raised including $5.6m from US Family Office
Lind facility paid out in full by end of July 2025
Significant headcount and cost reductions



CHM CDH17

CAR-T

Trial commenced: 6 patients treated
Dose level 1 completed: Stable disease 8mths
Dose level 2 commenced
9/9 successful GMP manufacturing runs



CHM CORE-NK

'OFF THE SHELF' NK

Dose finding completed
Frontline ADVENT AML commenced
2 CRi (Complete response with incomplete blood count recovery)

CHIMERIC THERAPEUTICS

CHM CDH17

Clinical Trial Update

August 2025

2025

CLINICAL PRELIMINARY RESULTS

CHM CDH17 DOSE LEVEL 1

50m Cells	Tumour Type	Status
Patient 1	CRC	No follow up
Patient 2	NET	Stable Disease until day 150 progression
Patient 3	CRC	Stable Disease at day 220 reduction 18%
Patient 4	CRC	Progressive Disease at day 28

CRC= Colorectal Cancer (Bowel Cancer)
NET= NeuroEndocrine Tumor (Intestinal NET)

CLINICAL PRELIMINARY RESULTS

CHM CDH17 DOSE LEVEL 2

150m Cells	Tumour Type	Status
Patient 5	CRC	Stable Disease 12% reduction
Patient 6	NET	Manufactured to be treated
Patient 7	NET	Manufactured to be treated

CRC= Colorectal Cancer (Bowel Cancer)
NET= NeuroEndocrine Tumor (Intestinal NET)

CLINICAL PRELIMINARY RESULTS

103-003: 45 yo F with CRC treated at DL #2 (150 million CAR+ T-cells)



	Baseline	28days
Lung Lesion	2.5cm	2.2cm

CLINICAL PROGRAM NEXT STEPS

CHM CDH17 DOSE LEVEL Yet to be determine

150m Cells	Tumour Type	Status
Patient 8	CRC	Manufactured to be treated
Patient 9	CRC	Awaiting manufacturing
Patient 10	NET	Awaiting manufacturing

CRC= Colorectal Cancer (Bowel Cancer)
NET= NeuroEndocrine Tumor (Intestinal NET)

WHAT HAVE WE LEARNT SO FAR?

The Phase 1/2 Clinical Trial of CHM-2101 (CDH17) with four clinical sites are actively recruiting

Dose Level #1 (50 million CDH17 CAR+ T-cells) is safe

- Four of 4 treated subjects with evidence of expansion and persistence for at least 28 days
  - All AEs were associated with lymphodepleting chemotherapy and were self-limited
  - No Dose-limiting Toxicities (DLTs)
  - No on-target/off-tumor effects
  - No >grade 2 non-heme AEs

One subject with grade 1 CRS experienced T-cell expansion during week 2

- CAR T-cell persistence for >6 months

Enrollment to Dose Level #2 (150 million CDH17 CAR+ T-cells) is ongoing

- Two subjects have been assigned to DL#2 (1 without DLT / 1 pending treatment)
- One subject treated
  - No Dose-limiting Toxicities (DLTs)
  - No on-target/off-tumor effects
  - No >grade 2 non-heme AEs

Manufacturing is complete / treatment is pending for 3 additional subjects

CHIMERIC THERAPEUTICS

CHM CORE-NK

Clinical Trial Update

August 2025

2025

CHM CORE-NK TRIALS OPEN

Phase 1b clinical trials being lead by partner institutions

CHM CORE-NK
'OFF THE SHELF' NK

Technology from:

CASE WESTERN RESERVE UNIVERSITY

PHASE 1B TRIAL OPEN	PHASE 1B TRIAL OPEN
MD Anderson	Case Western

OFF THE SHELF: AKA ALLOGENEIC

NK cell expansion platform: Universal Donor

Positive Phase 1A Clinical Trial in Colorectal Cancer (CRC) and Acute Myeloid Leukaemia (AML)

Two ongoing Phase 1B Clinical Trials in AML

AML: Cohort 1 cleared, moved to dose expansion for Cohort 2

Our partners MD Anderson and Case Western are supporting the majority share of the cost of these two trials

AML PHASE 1B COMBINATION CLINICAL TRIAL OPEN

CHM CORE-NK + AZA + VEN in front-line Acute Myeloid Leukaemia

Clinical Trials.gov Identifier: NCT05834244

THE UNIVERSITY OF TEXAS MD Anderson Cancer Center



CORE NK CELLS

FDA REGISTERED
CHEMOTHERAPY

FDA REGISTERED
BLOOD CANCER DRUG

Funded by our partners MD Anderson Cancer Centre

CHIMERIC THERAPEUTICS

CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS

Complete response in AML in two patient of first three dosed

2 / 3 patients

DIAGNOSIS: AML

Not eligible for Chemo or Stem Cell Transplant

SAFETY: No dose limiting toxicities, no cytokine release syndrome, no GvHD



CRi = no signs of cancer in response to treatment
Blood count yet to recover (standard for AML patients)

CHIMERIC THERAPEUTICS

CHIMERIC

PIONEERS IN CELL THERAPY

investors@chimerictherapeutics.Com



2025